The trifecta of a company with above-average growth prospects and above-average starting income at a below-average valuation is incredibly potent. It's also quite rare to find such a stock.
But pharmaceutical company Merck (NYSE: MRK) seems to fit the bill. Let's dig deeper and discuss four reasons why the pharma stock is arguably a no-brainer buy-and-hold candidate over the long haul because it offers growth as well as income that makes it appealing to multiple types of investors.
Merck is best known for its top-selling cancer drug called Keytruda, which is on pace to exceed $20 billion in net sales in 2022. But with six other medicines or vaccine franchises and its COVID-19 antiviral therapeutic Lagevrio each on track to surpass at least $1 billion in net sales this year, the company's portfolio is more than just the most dominant cancer therapy on the planet.
For further details see:
4 Reasons to Buy This Hybrid of a Growth and Income Stock